Testing a Tumor Vaccine Plus Vorasidenib for IDH1 Mutant Lower Grade Glioma That Came Back
Original title: ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, mostly checking how safe the treatment is.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a tumor vaccine given with a drug called vorasidenib.
Who this trial is for. This trial is for adults whose IDH1 mutant lower grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has come back. It tests a vaccine called PEPIDH1M given with vorasidenib, a drug that blocks mutant IDH1 and IDH2.
Where it stands. There are no results yet. The study is looking at how safe this pairing is, and how well it works. Those answers are not in.
What this means, and what it doesn't
What it could mean: This is one of the ways new options get tested. If your tumor is an IDH1 mutant lower grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that came back, you could ask your care team about this study.
What it doesn't mean: This does not mean the vaccine and drug work. A trial is a test, not a proven treatment. Joining a study is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.